P-31 SHORT-TERM EFFICACY AND SAFETY OF LOLA THERAPY IN PATIENTS WITH CIRRHOSIS AND MINIMAL HEPATIC ENCEPHALOPATHY: A REAL-LIFE COHORT STUDY
| Autor: | Fátima Higuera-De La Tijera, AB Moreno-Cobos, Christian Hinojosa-Segura, Diana Montemira-Orozco, Imran Cruz-Reyes, Juana Zavala-Ramírez, Daniel Santana-Vargas, Alfredo Servín-Caamaño, Juan Miguel Abdo-Francis, José Luis Pérez-Hernández |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Annals of Hepatology, Vol 28, Iss , Pp 100933- (2023) |
| Druh dokumentu: | article |
| ISSN: | 1665-2681 26882477 |
| DOI: | 10.1016/j.aohep.2023.100933 |
| Popis: | Introduction and Objectives: Minimal hepatic encephalopathy (MHE) is associated with the risk of accidents, falls, and impaired quality of life. Treatment with L-ornithine L-aspartate (LOLA) could be an effective strategy. This study aimed to verify the efficacy and safety of LOLA treatment in a real-life cohort of cirrhotic patients with MHE. Materials and Methods: Cirrhotic patients with MHE were included. Those who had received any anti-ammoniacal measure or with alcohol consumption in the last six months, creatinine > 1.5 mg/dL, or previously known chronic kidney disease were excluded. The diagnosis of MHE was made using the psychometric hepatic encephalopathy score (PHES) and the critical flicker frequency (CFF). MHE patients received LOLA 6 g t.i.d. for three days and were reassessed with PHES and CFF. The project was approved by the local research and ethics committees. Results: 98 cirrhotic patients were evaluated; 38 (38.8%) had baseline MHE, 26 (68.4%) women, mean age 53.3±8.8 years, median education nine years (range 0-15). According to Child-Pugh: 26 (68.4%) A, 9 (23.7%) B, and 3 (7.9%) C. The median MELD was 11 (range 6-21), and MELD-Na 12 (range 6-26). Intention to treat analysis: According to PHES, 30(78.9%) patients showed remission of MHE (p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|